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This paper describes a worldwide interlaboratory study on PCDDS, PCDFs, dioxin-like PCBs, indicator PCBs and 
PBDEs in no-artificially fortified human blood plasma. The study took place from January 2006 to July 2006. The 
test material was sent to 10 participants from 7 countries. The study design involved the analysis of one test sample 
in triplicate. The results reported for PCDDs were satisfactory with a range of relative standard deviation (RSD) of 9-
25%, except OCDD (RSD 61%). Four congeners (2, 3, 4, 7, 8-PentaCDF, 1, 2, 3, 4, 7, 8-HexaCDF, 1, 2, 3, 6, 7, 8-
HexaCDF, 1, 2, 3, 4, 6, 7, 8-HeptaCDF) out of the ten PCDFs were measured reliably (RSD 11-28%). Good results 
were achieved for PCBs except the CB 77 (RSD 48%), CB 28 (RSD 50%), CB 52 (RSD 63%), CB 101 (RSD 60%). 
Levels of PBDEs in the test material were very low (i.e. ng/L range). Results showed that a further improvement for 
BDE 47 (RSD 114%) and BDE 99 (RSD 81%) is needed. Too scarce results were reported for BDE 209 to assess its 
performances. The study also highlighted the issue of lipid determination. Enzymatic methods provide higher results 
compared to gravimetric methods. As scientific literature compares human exposure to these contaminants on a lipid 




Human biomonitoring focused on the exposure to PCDDs, PCDFs, PCBs and PBDEs demands the availability of 
reliable data on the concentration of these contaminants in adipose tissues, blood and breast milk. The difficulties in 
obtaining human adipose tissues limit its use in epidemiological studies. Breast milk and blood collection are a much 
less invasive procedure but they present significant analytical challenges. Breast milk has the advantage to have high 
content of fat and high levels of target compounds compared to serum, making the extraction easier and the precision 
of the measurement on lipid weight basis easier. Since the mid-eighties, the World Health Organisation (WHO) has 
coordinated programme on possible health risks of those contaminants, especially in infants, due to exposure through 
contaminated breast milk. It has however the double disadvantage to be limited to a specific part of the general 
population and to require great care concerning the time point at which samples are collected in regards of toxicant 
depuration while breast feeding is taking place. Blood then appears as an interesting alternative as it can be easily 
obtained but it has the disadvantage to lower the target compound levels, as the lipid content is below 1% by weight. 
A previous international intercalibration study on PCDD/Fs in human milk and blood already pointed out that the 
RSDs of the data from blood tent to be systematically larger for a given PCDD/Fs congener than the data from milk1. 
This survey sums up the analytical performances of laboratories for PCDD/Fs, for some PCBs and also for PBDEs in 
blood more than fifteen years after the last exercise. 
 
Materials and Methods 
 
Test Material 
The test material consisted of naturally contaminated human blood plasma not fortified with standards. It represents 
an aliquot of a pool of 5000 Belgian male and female donors aged from 18 to 65 years old. Participants received a 
sub-sample of 60-70 ml from a homogeneous batch of approximately one litre. The samples were shipped frozen 
(packed dry ice) and stored in a sealed amber glass vial. Most of the samples arrived frozen. For those damaged or 
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defrost during transport, they were immediately replaced. Thus, all the participants received the material in the 
requested conditions. The batch sample was tested for homogeneity before shipping. Six sub-samples of 20 ml were 
randomly sampled from six different bottles. Target analytes were analyzed under repeatability conditions and RSDs 
between 3% and 10% were achieved for the different congeners. 
 
Target compounds 
The content in all the seventeen 2,3,7,8 toxic PCDD/Fs, the twelve dioxin-like PCBs (77, 81, 105, 114, 118, 123, 
126, 156, 157, 167, 169, 189), the six indicator PCBs (28, 52, 101, 138, 153, 180), and eight PBDEs (28, 47, 99, 100, 
153, 154, 183, 209) were measured by GC-HRMS.  
 
Methods used by the participants 
Participants applied their own extraction and clean-up procedures. Three laboratories performed an acidic pre-
treatment of the sample prior to extraction; seven laboratories not. All laboratories spiked with the seventeen 13C-
labelled 2,3,7,8 substituted PCDD/Fs, the twelve 13C-labelled dioxin-like PCBs, the six 13C-labelled indicator PCBs 
and the seven or eight 13C-labelled PBDEs. Extraction methods were mainly liquid/liquid (7x) and C18-solid phase 
extraction (SPE) (3x). Classical multi-steps clean-up on columns with different adsorbents (silica, alumina, florisil 
and carbon) were carried, each laboratory has its own validated procedure. Different GC columns and different 
standard solutions were used but all used high-resolution sector instruments operating in electron impact at 10000 
resolution in selected ion monitoring mode (except lab 7 for mono- and di-ortho PCBs). An overview of the GC-
HRMS methods used is given in Table 1.  
 
Lipid determination 
Participants performed a separate lipid determination on the plasma. They used their own lipid determination 




The statistical treatment of the data was performed on ‘results corrected for blanks’. For several reasons, some 
laboratories estimated not relevant or not necessary to remove the blank, others lost the blank. For those labs, the 
‘results not corrected for blanks’ were used. 
To determine the consensus value, we have selected the following approach. For all target analytes, median were 
calculated for all reported results. ‘ND’, ‘<LOD’ or ‘<LOQ’ were not used for assessment of the median due to the 
wide range of LOD/LOQ reported by participants. In addition, obvious outliers above ± 2 standard deviation (SD) 
were removed to assign values. 
 
Results and discussion 
 
Table 2 summarizes the performances. Due to low levels, high dispersion and few reported results, the following 
congeners (2,3,7,8-TetraCDF; 1,2,3,7,8-PentaCDF; 1,2,3,7,8,9-HexaCDF; 1,2,3,4,7,8,9-HepaCDF, OctaCDF, PCB 
81, PBDE 28, PBDE 209) were not statistically treated. According to the provided data, only an indicative value 
‘less than’ was reported. Basic statistics calculated for each analyte include the median, the mean and the relative 
standard deviation RSD (%). RSDs between 9% and 25% were obtained for PCDDs except for OCDD (61%) for 
which two laboratories reported much higher values. We already mentioned the difficulty to reliably measure five
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Table 1 : (HR)GC-HRMS conditions for the participating laboratories. 
Compounds Lab 1 Lab 2 Lab 3 Lab 4 Lab 5 Lab 6 Lab 7 Lab 8 Lab 9 Lab10 
PCDD/Fs 
          
Column 1 (sat. phase, DB-5MS  DB5-MS DB5 DB5-MS DB5-MS DB5 BPX-5 VF5-MS DB5-MS Not measured 
length, ID, Film thickness) 60m x 0.25mm x 0.25µm 60m x 0.25mm x 0.10µm 30m x 0.25mm x 0.10µm 30m x 0.25mm x 0.25µm 60m x 0.25mm x 0.25µm 60m x 0.25mm x 0.10µm 50m x 0,32mm x 0,17µm 50m x 0.20mm x 0.33µm 30m x 0.25mm x 0.25µm  
run time 53 min 50 min 40 min 30 min 45 min 45 min 40 min 50 min 47.5 min  
Column 2 (sat. phase, 
 RTX-2330         
length, ID, Film thickness) 
 
60m x 0.25mm 
x 0.2µm         
run time 
 55 min         
Detector HRMS HRMS HRMS HRMS HRMS HRMS HRMS HRMS HRMS   
 
          
Non-Ortho PCBs 
          
Column 1 (sat. phase, DB-5MS  DB5 HT8 DB5-MS DB5-MS DB5 BPX-5 VF5-MS  HT8 Not measured 
length, ID, Film thickness) 60m x 0.25mm x 0.25µm 60m x 0.25mm x 0.10µm 50m x 0.22mm x 0.25µm 30m x 0.25mm x 0.25µm 60m x 0.25mm x 0.25µm 60m x 0.25mm x 0.10µm 50m x 0,32mm x 0,17µm 50m x 0.20mm x 0.33µm 60m x 0.25mm x 0.20µm  
run time 53 min 45 min 40 min 30 min 45 min 45 min 40 min 50 min 55 min  
Detector HRMS HRMS HRMS HRMS HRMS HRMS HRMS HRMS HRMS  
 
          
Mono-ortho PCBs 
          
Column 1 (sat. phase, DB-5MS  HT8 HT8 DB5-MS DB5-MS DB5 HT5 HT8  HT8 DB5-MS 
length, ID, Film thickness) 60m x 0.25mm x 0.25µm 60m x 0.25mm x 0.20µm 50m x 0.22mm x 0.25µm 30m x 0.25mm x 0.25µm 60m x 0.25mm x 0.25µm 60m x 0.25mm x 0.10µm 25m x 0,22mm x 0,25µm 25m x 0.22mm x 0.25µm 60m x 0.25mm x 0.20µm 30m x 0.25mm x 0.25µm 
run time 53 min 50 min 40 min 30 min 45 min 45 min 30 min  30 min 55 min 30 min 
Detector HRMS HRMS HRMS HRMS HRMS HRMS LRMS HRMS HRMS HRMS 
 
          
Di-ortho PCBs 
          
Column 1 (sat. phase, Not measured HT8 HT8 DB5-MS DB5-MS DB5-MS HT5 HT8  HT8 DB5-MS 
length, ID, Film thickness) 
 
60m x 0.25mm 
x 0.20µm 
50m x 0.22mm 
x 0.25µm 
30m x 0.25mm 
x 0.25µm 
60m x 0.25mm 
x 0.25µm 
60m x 0.25mm 
x 0.20µm 
25m x 0,22mm 
x 0,25µm 
25m x 0.22mm 
x 0.25µm 
60m x 0.25mm 
x 0.20µm 
30m x 0.25mm 
x 0.25µm 
run time 
 50 min 40 min 30 min 45 min 45 min 30 min 30 min 55 min 30 min 
Detector 
 HRMS HRMS HRMS HRMS HRMS LRMS HRMS HRMS HRMS 
 
          
PBDEs 
          
Column 1 (sat. phase, DB-5MS   DB-5HT Not measured Not measured Not measured DB1 Not measured HT8  UB5 premium DB5-HT 
length, ID, Film thickness) 60m x 0.25mm x 0.25µm 15m x 0.25mm x 0.10µm    10m x 0.18mm x 0.18 µm  25m x 0.22mm x 0.25µm 15m x 0.25mm x 0.10µm 15m x 0.25mm x 0.10µm 
run time 53 min 30 min    30 min  30 min 30 min 20 min 
Detector HRMS HRMS       HRMS  HRMS HRMS HRMS 
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Table 2: Overview of major statistical parameters 
Congeners  n Median  mean RSD Outliers 
Dioxins (pg/L)   (pg/L) (pg/L) (%)  
2, 3, 7, 8 - TetraCDD  22 9,5  9,9 22 1 
1, 2, 3, 7, 8 - PentaCDD  22 32,0  32,3 9 0 
1, 2, 3, 4, 7, 8 - HexaCDD  22 17,3  17,2 21 1 
1, 2, 3, 6, 7, 8 - HexaCDD  24 122,0  119,6 9 1 
1, 2, 3, 7, 8, 9 - HexaCDD  22 17,4  18,5 22 1 
1, 2, 3, 4, 6, 7, 8 - HeptaCDD  24 145,4  152,8 25 2 
OctaCDD  24 1390,0  1635,4 61 4 
Furans (pg/L)       
2, 3, 7, 8 - TetraCDF  10 <5,0  <5,0  - - 
1, 2, 3, 7, 8 - PentaCDF  7 <5,0  <5,0  - - 
2, 3, 4, 7, 8 - PentaCDF  24 82,5  78,6 14 0 
1, 2, 3, 4, 7, 8 - HexaCDF  22 24,0  23,2 14 1 
1, 2, 3, 6, 7, 8 - HexaCDF  22 28,0  28,0 11 1 
1, 2, 3, 7, 8, 9 - HexaCDF  2 <5,0  <5,0 - - 
2, 3, 4, 6, 7, 8 - HexaCDF  18 7,9  9,8 57 1 
1, 2, 3, 4, 6, 7, 8 - HeptaCDF  23 35,0  34,9 28  
1, 2, 3, 4, 7, 8, 9 - HeptaCDF  3 <5,0  <5,0  - - 
OctaCDF  5 <40,0  <40,0  - - 
dioxin like PCBs (pg/L)       
PCB 77 (non-ortho)  16 186,1  171,1 48 0 
PCB 81 (non-ortho)  7 <100,0  <100,0 - - 
PCB 126 (non-ortho)  22 247,9  249,4 14 3 
PCB 169 (non-ortho)  24 334,0  349,7 19 1 
PCB 105 (ortho)  26 11740,0  12131,1 10 2 
PCB 114 (ortho)  20 3873,0  3982,9 16 1 
PCB 118 (ortho)  26 74702,4  72948,0 13 1 
PCB 123 (ortho)  19 830,0  776,9 26 2 
PCB 156 (ortho)  26 56128,6  55926,7 9 2 
PCB 157 (ortho)  26 10412,2  10600,6 8 2 
PCB 167 (ortho)  26 16354,4  16706,4 9 1 
PCB 189 (ortho)  26 8606,9  8604,0 12 2 
Indicator PCBs (ng/L)       
PCB 28  16 11,1  11,48 50 0 
PCB 52  16 7,9  7,7 63 0 
PCB 101  19 5,7  5,9 60 1 
PCB 138  25 290,7  289,5 17 3 
PCB 153  25 507,0  511,3 10 2 
PCB 180  24 443,7  447,4 7 3 
PBDEs (ng/L)       
PBDE 28  10 <3,0  <3,0 - - 
PBDE 47  16 6,4  9,7 114 1 
PBDE 99  16 2,5  3,4 84 2 
PBDE 100  13 1,5  1,7 51 0 
PBDE 153  16 6,3  6,0 22 0 
PBDE 154  11 0,4  0,5 68 2 
PBDE 183  14 1,6  1,7 40 1 
PBDE 209  5 <100  <100 - - 
Total Lipids (g/L)       
gravimetric  15 4,6  4,6 13 0 
enzymatic  18 5,4  5,6 6 2 
ANALYSIS III (QUALITY CONTROL AND REFERENCE MATERIALS)
Organohalogen Compounds Vol 69 (2007) P-051 1279
 5
out of the ten PCDFs. RSDs between 11% and 57%. No major difficulties were observed for dioxin-like PCBs 
(RSDs between 8% and 26%) except CB 77 and 81. The large RSD for CB 77 is due to the conjugated effect of its 
high ubiquity in procedural blank samples and its weak level in the human plasma. The same reasons can also 
explain the high variability observed for CB 28, 52, 101 (RSDs > 50%). Less data were reported for PBDEs and, 
compared with the results of chlorinated compounds, the RSDs for most of the PBDEs were higher. This indicates an 
immature QA/QC approach for the analysis of PBDEs in serum samples at background European levels. 
Finally, Table 2 also shows the results of the lipid determination performed on the test material. Ten laboratories 
submitted results. These were evenly divided between gravimetric and enzymatic methods (both methods reported by 
laboratory 2). Enzymatic methods tend to yield higher results (median of 5,4 g/L compared to the median of 4,6 g/L). 
Dispersion of gravimetric methods is greater than for enzymatic (SD of 0,3 g/L compared 0,6 g/L). This is probably 
due to the fact that enzymatic methods are generally performed by automated systems using commercial kits whereas 
gravimetric methods are manual and more dependent on the skill of the operator. As scientific literature compares 
human exposure to these contaminants on a lipid weight basis in serum, the results presented here point out the 
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